Prognostic Value of the C-Reactive Protein-albumin-lymphocyte Index For Patients With Recurrent οr Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab

The CALLY index may serve as a useful and independent prognostic biomarker for R/M HNSCC patients undergoing nivolumab therapy, reflecting systemic status and predicting treatment outcomes.